CDKN2A and brain stem glioma: For example, a preclinical trial using PD-0332991 (PD), a CDK4/6 inhibitor, that induces cell cycle arrest both in vitro and in vivo in high-grade brainstem glioma cell lines enhanced survival when used in combination with radiotherpy in a genetically engineered, PDGF-B overexpressing, Ink4a-ARF and p53 deficient brainstem glioma mouse model [205].